『Background of ICI & Highlights in Oncology』のカバーアート

Background of ICI & Highlights in Oncology

Background of ICI & Highlights in Oncology

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

  • Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 years
  • Multiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011
  • Robust survival benefit seen with ICI across multiple tumor types
  • IV ICI therapy requires line access and creates increased chair time
  • Subcutaneous (SC) ICI options provide increased patient convenience and operational efficiencies
  • SC products may increase nurse resources due to time spent administering
まだレビューはありません